FDA panel to review Medtronic's Endeavor stent PMA (pre-market approval) in October:
This article was originally published in Clinica
An advisory panel from the US FDA is to convene in October in order to review the pre-market approval (PMA) application for Medtronic's Endeavor stent. The agency will announce the date and agenda for the meeting four to six weeks in advance. The PMA application was submitted last November, and was expected to be approved in mid-2007. The Minneapolis, Minnesota-based firm has now altered this expectation; Scott Ward, president of the cardiovascular business at Medtronic, said that approval was anticipated later this calendar year. Analyst Glenn Reicin, however, has described this expectation as an example of "perpetual overoptimism"; there is "no way" the FDA will approve it before 2008, he told the New York Times. The device was CE marked in 2005.
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.